Skip to main content
. 2019 Jan 22;21(5):669–677. doi: 10.1093/neuonc/noz016

Table 2.

Clinical characteristics of patients with IDH mutant grade II and grade III gliomas who experienced first episode of progression

Number of patients 147
Median age at diagnosis (range) 36.7 (18–64)
Male:female ratio 1.2:1
Histologic grade (%)
 WHO grade II 81 (55.1)
 WHO grade III 66 (44.9)
Molecular diagnosis (%)
 Astrocytic 95 (64.6)
 Oligodendroglial 52 (35.4)
Median follow-up
 Non-progressors 4.1 y
 Survivors 4.0 y